Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.

Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

Drug Metab Dispos. 2019 Jun;47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2.

PMID:
30940629
2.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.

Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18.

PMID:
30228112
3.

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease.

Cuerq C, Henin E, Restier L, Blond E, Drai J, Marçais C, Di Filippo M, Laveille C, Michalski MC, Poinsot P, Caussy C, Sassolas A, Moulin P, Reboul E, Charriere S, Levy E, Lachaux A, Peretti N.

J Lipid Res. 2018 Sep;59(9):1640-1648. doi: 10.1194/jlr.M085043. Epub 2018 Jul 18.

4.

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.

Le Saux O, Bourmaud A, Rioufol C, Colomban O, Guitton J, Schwiertz V, Regnier V, You B, Ranchon F, Maraval-Gaget R, Girard P, Chauvin F, Freyer G, Tod M, Henin E, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):319-327. doi: 10.1007/s00280-018-3612-x. Epub 2018 Jun 15.

PMID:
29948022
5.

Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology.

Berges A, Cerou M, Sahota T, Liefaard L, Ambery C, Zamuner S, Chen C, Hénin E.

Toxicol Sci. 2018 Sep 1;165(1):50-60. doi: 10.1093/toxsci/kfy122.

PMID:
29788384
6.

Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?

Ranchon F, Vantard N, Henin E, Bachy E, Sarkozy C, Karlin L, Bouafia-Sauvy F, Gouraud A, Schwiertz V, Bourbon E, Baudouin A, Caffin AG, Vial T, Salles G, Rioufol C.

Hematol Oncol. 2018 Apr;36(2):399-406. doi: 10.1002/hon.2479. Epub 2017 Oct 6.

PMID:
28983943
7.

Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.

Hénin E, Honorat M, Guitton J, Di Pietro A, Payen L, Tod M.

Biopharm Drug Dispos. 2017 Jul;38(5):351-362. doi: 10.1002/bdd.2069. Epub 2017 Mar 23.

PMID:
28207160
8.

Oral dosage form administration practice in children under 6 years of age: A survey study of paediatric nurses.

Walch AC, Henin E, Berthiller J, Dode X, Abel B, Kassai B, Lajoinie A; EREMI Group.

Int J Pharm. 2016 Sep 25;511(2):855-63. doi: 10.1016/j.ijpharm.2016.07.076. Epub 2016 Aug 2.

PMID:
27492017
9.

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes.

Pierrillas PB, Tod M, Amiel M, Chenel M, Henin E.

AAPS J. 2016 Sep;18(5):1262-1272. doi: 10.1208/s12248-016-9936-8. Epub 2016 Jun 21.

PMID:
27329303
10.

Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.

Hénin E, Meille C, Barbolosi D, You B, Guitton J, Iliadis A, Freyer G.

Breast Cancer Res Treat. 2016 Apr;156(2):331-41. doi: 10.1007/s10549-016-3760-9. Epub 2016 Mar 22.

PMID:
27002506
11.

Oral drug dosage forms administered to hospitalized children: Analysis of 117,665 oral administrations in a French paediatric hospital over a 1-year period.

Lajoinie A, Henin E, Nguyen KA, Malik S, Mimouni Y, Sapori JM, Bréant V, Cochat P, Kassai B.

Int J Pharm. 2016 Mar 16;500(1-2):336-44. doi: 10.1016/j.ijpharm.2016.01.048. Epub 2016 Jan 22.

PMID:
26804927
12.

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors.

Pierrillas PB, Tod M, Amiel M, Chenel M, Henin E.

AAPS J. 2016 Mar;18(2):404-15. doi: 10.1208/s12248-015-9862-1. Epub 2016 Jan 12.

13.
14.

Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions.

Hénin E, Bergstrand M, Weitschies W, Karlsson MO.

Pharm Res. 2016 Mar;33(3):751-62. doi: 10.1007/s11095-015-1824-x. Epub 2015 Nov 9.

PMID:
26553354
15.

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).

You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G.

Cancer Chemother Pharmacol. 2015 Nov;76(5):939-48. doi: 10.1007/s00280-015-2866-9. Epub 2015 Sep 21.

PMID:
26391155
16.

Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug development.

Glatard A, Berges A, Sahota T, Ambery C, Osborne J, Smith R, Hénin E, Chen C.

Toxicol Appl Pharmacol. 2015 Oct 15;288(2):240-8. doi: 10.1016/j.taap.2015.07.022. Epub 2015 Jul 29.

PMID:
26232187
17.

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, Hénin E.

CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):277-85. doi: 10.1002/psp4.34. Epub 2015 Apr 24.

18.

Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.

Bourmaud A, Henin E, Tinquaut F, Regnier V, Hamant C, Colomban O, You B, Ranchon F, Guitton J, Girard P, Freyer G, Tod M, Rioufol C, Trillet-Lenoir V, Chauvin F.

BMC Res Notes. 2015 Jul 4;8:291. doi: 10.1186/s13104-015-1231-8.

19.

[Oral formulation of choice for children].

Lajoinie A, Henin E, Kassai B.

Arch Pediatr. 2015 Aug;22(8):877-85. doi: 10.1016/j.arcped.2015.05.012. Epub 2015 Jul 2. Review. French.

PMID:
26141805
20.

Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.

Philippe M, Hénin E, Bertrand Y, Plantaz D, Goutelle S, Bleyzac N.

AAPS J. 2015 Sep;17(5):1157-67. doi: 10.1208/s12248-015-9779-8. Epub 2015 May 15.

21.

Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.

El-Madani M, Hénin E, Lefort T, Tod M, Freyer G, Cassier P, Valette PJ, Rodriguez-Lafrasse C, Berger F, Guitton J, Lachuer J, Slimane K, Barrois C, You B.

Future Oncol. 2015;11(10):1511-8. doi: 10.2217/fon.15.49.

PMID:
25963428
22.

Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials.

Ranchon F, Vial T, Rioufol C, Hénin E, Falandry C, Freyer G, Trillet-Lenoir V, Le Tourneau C, You B.

Crit Rev Oncol Hematol. 2015 May;94(2):189-200. doi: 10.1016/j.critrevonc.2014.12.014. Epub 2015 Jan 3. Review.

PMID:
25638703
23.

Solid oral forms availability in children: a cost saving investigation.

Lajoinie A, Henin E, Kassai B, Terry D.

Br J Clin Pharmacol. 2014 Nov;78(5):1080-9. doi: 10.1111/bcp.12442.

24.

Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.

Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B.

Gynecol Oncol. 2014 Jun;133(3):460-6. doi: 10.1016/j.ygyno.2014.04.003. Epub 2014 Apr 12.

PMID:
24726614
25.

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.

Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B.

Br J Cancer. 2014 Mar 18;110(6):1517-24. doi: 10.1038/bjc.2014.75. Epub 2014 Feb 20.

26.

A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O, You B.

Ann Oncol. 2014 Jan;25(1):41-56. doi: 10.1093/annonc/mdt382. Review.

PMID:
24356619
27.

Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).

Hénin E, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Freyer G, Vidal M, Goldwasser F, Tod M.

Cancer Chemother Pharmacol. 2014 Feb;73(2):287-97. doi: 10.1007/s00280-013-2352-1. Epub 2013 Nov 20.

PMID:
24253177
28.

Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoprotein.

Martinez L, Arnaud O, Henin E, Tao H, Chaptal V, Doshi R, Andrieu T, Dussurgey S, Tod M, Di Pietro A, Zhang Q, Chang G, Falson P.

FEBS J. 2014 Feb;281(3):673-82. doi: 10.1111/febs.12613. Epub 2014 Jan 17.

29.

Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.

Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, Jestin-Le Tallec V, Kirsher S, Leyronnas C, Ligeza-Poisson C, Ramdane S, Salavt J, Van-Hult S, Vannetzel JM, Freyer G, Tod M, Falandry C.

J Geriatr Oncol. 2013 Jan;4(1):48-57. doi: 10.1016/j.jgo.2012.06.004. Epub 2012 Aug 3.

PMID:
24071492
30.

Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.

You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ.

Br J Cancer. 2013 May 14;108(9):1810-6. doi: 10.1038/bjc.2013.123. Epub 2013 Apr 16.

31.

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

Hamizi S, Freyer G, Bakrin N, Henin E, Mohtaram A, Le Saux O, Falandry C.

Onco Targets Ther. 2013;6:89-94. doi: 10.2147/OTT.S27733. Epub 2013 Feb 14.

32.

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.

Choy S, Hénin E, van der Walt JS, Kjellsson MC, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):1-10. doi: 10.1007/s10928-012-9281-1. Epub 2012 Nov 24.

PMID:
23179858
33.

A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Hénin E, Bergstrand M, Standing JF, Karlsson MO.

AAPS J. 2012 Jun;14(2):155-63. doi: 10.1208/s12248-012-9324-y.

34.

Predictors of prescription errors involving anticancer chemotherapy agents.

Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N, Franchon E, Dussart C, Henin E, Colomban O, Girard P, Freyer G, Rioufol C.

Eur J Cancer. 2012 May;48(8):1192-9. doi: 10.1016/j.ejca.2011.12.031. Epub 2012 Jan 28.

PMID:
22285178
35.

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs.

Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S, Broussais F, You B, Tartas S, Souquet PJ, Dussart C, Falandry C, Henin E, Freyer G, Rioufol C.

BMC Cancer. 2011 Nov 8;11:478. doi: 10.1186/1471-2407-11-478.

36.

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G.

Br J Clin Pharmacol. 2012 Apr;73(4):597-605. doi: 10.1111/j.1365-2125.2011.04125.x.

37.

Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.

Paule I, Tod M, Hénin E, You B, Freyer G, Girard P.

Cancer Chemother Pharmacol. 2012 Feb;69(2):447-55. doi: 10.1007/s00280-011-1714-9. Epub 2011 Aug 2.

PMID:
21809035
38.

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

Ternant D, Hénin E, Cartron G, Tod M, Paintaud G, Girard P.

Br J Clin Pharmacol. 2009 Oct;68(4):561-73. doi: 10.1111/j.1365-2125.2009.03494.x.

39.

Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Hénin E, Tod M, Trillet-Lenoir V, Rioufol C, Tranchand B, Girard P.

Clin Pharmacokinet. 2009;48(6):359-69. doi: 10.2165/00003088-200948060-00002.

PMID:
19650675
40.

Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.

You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P.

Prostate. 2009 Sep 1;69(12):1325-33. doi: 10.1002/pros.20978.

PMID:
19475643
41.

A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.

Hénin E, You B, VanCutsem E, Hoff PM, Cassidy J, Twelves C, Zuideveld KP, Sirzen F, Dartois C, Freyer G, Tod M, Girard P.

Clin Pharmacol Ther. 2009 Apr;85(4):418-25. doi: 10.1038/clpt.2008.220. Epub 2008 Dec 10.

PMID:
19078948
42.

Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.

You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Hénin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P.

Clin Biochem. 2008 Jul;41(10-11):785-95. doi: 10.1016/j.clinbiochem.2008.04.001. Epub 2008 Apr 11.

PMID:
18440312
43.

[Issues of the study of patient compliance to treatment with oral anticancer chemotherapy: advantages of pharmacokinetics-pharmacodynamics modelisation].

Hénin E, You B, Tranchand B, Freyer G, Girard P.

Therapie. 2007 Mar-Apr;62(2):77-85. Epub 2007 Jun 21. French.

PMID:
17582305
44.

Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.

Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, Vermot-Desroches C, Tranchand B, Girard P.

Clin Pharmacokinet. 2007;46(5):417-32.

45.

Tissue distribution of human calcium-binding protein (28 000 g mol-1).

Parkes CO, Thomasset M, Baimbridge KG, Henin E.

Eur J Clin Invest. 1984 Jun;14(3):181-3.

PMID:
6432546

Supplemental Content

Support Center